FindTrial
Sign In

All patients will receive BAY 43-9006 400 mg bid for the period of 8 weeks.

2 trials

Sponsors

Academic Medical Center, University of Amsterdam, Department of Urology, Academic Medical Center, University of Amsterdam. Department of Urology

Conditions

All patients with histological proven prostate cancer who are eligible for laparoscopic radical prostatectomy will be asked to participate in the BAY 43-9006 study.All patients with renal cell cancer who are candidates for a partial or radical nephrectomy, will be asked to participate in the BAY 43-9006 study.

Unknown Phase

A single center open-label uncontrolled study to investigate the PSA and tumor vascularization response rate of neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable prostate cancer.
Active, not recruitingNL-OMON28891
Academic Medical Center, University of Amsterdam. Department of UrologyAll patients with histological proven prostate cancer who are eligible for laparoscopic radical prostatectomy will be asked to participate in the BAY 43-9006 study.
Start: 2006-03-01Target: 30Updated: 2024-02-28
A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable renal cell cancer.
Active, not recruitingNL-OMON26901
Academic Medical Center, University of Amsterdam, Department of UrologyAll patients with renal cell cancer who are candidates for a partial or radical nephrectomy, will be asked to participate in the BAY 43-9006 study.
Start: 2006-03-01Target: 30Updated: 2024-02-28